HOLX vs. BDX, EW, IDXX, RMD, DXCM, STE, PODD, BAX, MASI, and GMED
Should you be buying Hologic stock or one of its competitors? The main competitors of Hologic include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), Baxter International (BAX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.
Hologic vs.
Becton, Dickinson and Company (NYSE:BDX) and Hologic (NASDAQ:HOLX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation.
87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of Hologic shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 1.9% of Hologic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Hologic received 276 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 69.04% of users gave Hologic an outperform vote while only 62.07% of users gave Becton, Dickinson and Company an outperform vote.
In the previous week, Becton, Dickinson and Company had 11 more articles in the media than Hologic. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 9 mentions for Hologic. Hologic's average media sentiment score of 1.39 beat Becton, Dickinson and Company's score of 1.19 indicating that Hologic is being referred to more favorably in the news media.
Becton, Dickinson and Company presently has a consensus price target of $219.22, indicating a potential upside of 25.85%. Hologic has a consensus price target of $77.42, indicating a potential upside of 18.45%. Given Becton, Dickinson and Company's higher possible upside, research analysts plainly believe Becton, Dickinson and Company is more favorable than Hologic.
Becton, Dickinson and Company has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.
Hologic has a net margin of 18.42% compared to Becton, Dickinson and Company's net margin of 8.47%. Hologic's return on equity of 19.72% beat Becton, Dickinson and Company's return on equity.
Becton, Dickinson and Company has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
Summary
Hologic beats Becton, Dickinson and Company on 13 of the 19 factors compared between the two stocks.
Get Hologic News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:HOLX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy HOLX Stock Free HOLX Stock Alerts